Selecting Third-Line Therapy to Treat HER2+ De Novo Metastatic Breast Cancer
1 Views
administrator
07/03/23
Options have recently expanded in the third-line setting for patients such as this 59-year-old woman with HER2+ de novo metastatic breast cancer.
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
-
Category
Show more
Facebook Comments
No comments found